Most patients with stage four cancer are not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. Our breakthrough technology is challenging that and aims to treat multiple tumors, in parallel, during a single session.
Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. RefleXion will work together with chemotherapy, immunotherapy and targeted drugs for potentially better outcomes.
Expands Series D financing by $40M HAYWARD, Calif.–(BUSINESS WIRE)– RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, today announced the successful completion of a $40 million extension to its Series D financing, which combined with $110 million raised in 2020, brings the total Series D financing […]
Hector Ruiz de Vinaspre is passionate about “disruptive tech”—so it’s no surprise that he’s won numerous national sales awards during his distinguished sales career. In his latest career move, he joins RefleXion Medical as director of sales, where he’s excited to once again sell ground-breaking, disruptive technology that could one day improve outcomes for metastatic […]
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.